Cargando…

Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant

INTRODUCTION: Insomnia diagnosis has been associated with a significant clinical and economic burden on patients and healthcare systems. This study examined changes in healthcare resource use (HCRU) and costs in insomnia patients before and after initiation of suvorexant treatment. METHODS: This ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kale, Hrishikesh P., Qureshi, Zaina P., Shah, Ruchit, Khandker, Rezaul, Botteman, Marc, Meng, Weilin, Benca, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478735/ https://www.ncbi.nlm.nih.gov/pubmed/34463922 http://dx.doi.org/10.1007/s12325-021-01891-8

Ejemplares similares

Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review
por: Benca, Ruth, et al.
Publicado: (2022)

Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer’s Disease Patients
por: Qureshi, Zaina P., et al.
Publicado: (2021)

Profile of suvorexant in the management of insomnia
por: Sutton, Eliza L
Publicado: (2015)

Suvorexant: a promising, novel treatment for insomnia
por: Lee-Iannotti, Joyce K, et al.
Publicado: (2016)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Suvorexant for insomnia in older adults: a perspective review
por: Tampi, Rajesh R, et al.
Publicado: (2018)

Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study
por: Hatano, Masakazu, et al.
Publicado: (2018)

Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
por: Toi, Norikazu, et al.
Publicado: (2018)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
por: Kishi, Taro, et al.
Publicado: (2019)

2420 Examining characteristics of placebo effects on trauma-related insomnia in a suvorexant trial
por: Uweh, Kimberly
Publicado: (2018)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
por: Herring, W. Joseph, et al.
Publicado: (2020)

Modeling acute care utilization: practical implications for insomnia patients
por: Chekani, Farid, et al.
Publicado: (2023)

Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance
por: Qureshi, Zaina P., et al.
Publicado: (2020)

Impact of Dementia-Related Behavioral Symptoms on Healthcare Resource Use and Caregiver Burden: Real-World Data from Europe and the United States
por: Chekani, Farid, et al.
Publicado: (2021)

Suvorexant for the prevention of delirium: A meta-analysis
por: Xu, Shu, et al.
Publicado: (2020)

Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes
por: Khandker, Rezaul, et al.
Publicado: (2022)

Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience
por: Matsumura, Takuma, et al.
Publicado: (2019)

Development and Temporal Validation of an Electronic Medical Record-Based Insomnia Prediction Model Using Data from a Statewide Health Information Exchange
por: Holler, Emma, et al.
Publicado: (2023)

Distinct effects of IPSU and suvorexant on mouse sleep architecture
por: Hoyer, Daniel, et al.
Publicado: (2013)

Is suvorexant a better choice than alternative hypnotics?
por: Kripke, Daniel F.
Publicado: (2015)

PT653. Experience using suvorexant to treat delirium
por: Fujiwara, Kodo, et al.
Publicado: (2016)

Suvorexant Poisoning in a Patient With Cirrhosis and Renal Failure
por: Ito, Hiroshi, et al.
Publicado: (2021)

(82) Effect of Suvorexant on COVID-19 Associated Delirium
por: Nazeer, Sahana, et al.
Publicado: (2022)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
por: Matsumoto, Tohru
Publicado: (2021)

Healthcare use in commercially insured youth with mental health disorders
por: Hugunin, Julie, et al.
Publicado: (2022)

Medical Costs Associated with Insomnia Treatment with Suvorexant Monotherapy in Japan: Results from a Retrospective Cohort Study Using a Large-Scale Claims Database
por: Uchiyama, Makoto, et al.
Publicado: (2022)

Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA
por: Estes, Stephanie J., et al.
Publicado: (2020)

Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs
por: McGaughey, Georgia, et al.
Publicado: (2014)

Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant
por: Booka, Eisuke, et al.
Publicado: (2017)

A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients
por: Li, Gang, et al.
Publicado: (2020)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
por: Sahrmann, John M, et al.
Publicado: (2023)

The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use
por: DiBonaventura, Marco, et al.
Publicado: (2015)

Wake Up America: National Survey of Patients’ and Physicians’ Views and Attitudes on Insomnia Care
por: Benca, Ruth M., et al.
Publicado: (2023)

Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database
por: Okuda, Shoki, et al.
Publicado: (2023)

PT654. Suvorexant induced restless legs syndrome; a case report
por: Ogihara, Tomomi, et al.
Publicado: (2016)

Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting
por: Tamura, Kiyoshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gibovq22fdcdq3i2jn39a2ijgt